TransMedics Group (TMDX) Competitors $119.27 +0.12 (+0.10%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TMDX vs. SOLV, PEN, STVN, IRTC, BLCO, GKOS, SLNO, NVST, LIVN, and WRBYShould you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), Soleno Therapeutics (SLNO), Envista (NVST), LivaNova (LIVN), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry. TransMedics Group vs. Its Competitors Solventum Penumbra Stevanato Group iRhythm Technologies Bausch + Lomb Glaukos Soleno Therapeutics Envista LivaNova Warby Parker Solventum (NYSE:SOLV) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Does the media prefer SOLV or TMDX? In the previous week, Solventum had 4 more articles in the media than TransMedics Group. MarketBeat recorded 18 mentions for Solventum and 14 mentions for TransMedics Group. Solventum's average media sentiment score of 0.83 beat TransMedics Group's score of 0.65 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in SOLV or TMDX? 99.7% of TransMedics Group shares are owned by institutional investors. 0.1% of Solventum shares are owned by company insiders. Comparatively, 7.0% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is SOLV or TMDX more profitable? TransMedics Group has a net margin of 13.49% compared to Solventum's net margin of 4.52%. Solventum's return on equity of 29.93% beat TransMedics Group's return on equity.Company Net Margins Return on Equity Return on Assets Solventum4.52% 29.93% 6.65% TransMedics Group 13.49%28.02%8.64% Do analysts recommend SOLV or TMDX? Solventum currently has a consensus target price of $85.44, indicating a potential upside of 14.61%. TransMedics Group has a consensus target price of $125.40, indicating a potential upside of 5.14%. Given Solventum's higher probable upside, research analysts plainly believe Solventum is more favorable than TransMedics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.42TransMedics Group 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.73 Which has more risk and volatility, SOLV or TMDX? Solventum has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Which has higher earnings and valuation, SOLV or TMDX? Solventum has higher revenue and earnings than TransMedics Group. Solventum is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolventum$8.25B1.57$478M$2.1634.51TransMedics Group$441.54M9.21$35.46M$1.9361.80 SummaryTransMedics Group beats Solventum on 9 of the 16 factors compared between the two stocks. Get TransMedics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TMDX vs. The Competition Export to ExcelMetricTransMedics GroupMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.06B$6.64B$5.75B$10.26BDividend YieldN/A1.21%5.88%4.63%P/E Ratio61.6926.6377.0126.57Price / Sales9.21194.20528.65122.51Price / Cash69.4621.6137.2060.49Price / Book17.514.9613.966.34Net Income$35.46M$176.38M$3.29B$270.99M7 Day Performance10.65%5.97%1.38%2.67%1 Month Performance-6.49%7.24%5.13%7.23%1 Year Performance-23.58%16.96%84.67%27.97% TransMedics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TMDXTransMedics Group2.7163 of 5 stars$119.27+0.1%$125.40+5.1%-21.2%$4.06B$441.54M61.69210Analyst ForecastSOLVSolventum2.1233 of 5 stars$75.17+3.4%$85.75+14.1%+3.3%$13.05B$8.25B34.8522,000Positive NewsAnalyst ForecastPENPenumbra4.787 of 5 stars$285.01+1.3%$302.93+6.3%+40.2%$11.12B$1.19B75.804,500Positive NewsSTVNStevanato GroupN/A€24.90+3.1%N/A+42.3%€7.54B€1.19B46.115,521Gap UpIRTCiRhythm Technologies1.1865 of 5 stars$183.98+1.6%$163.82-11.0%+136.6%$5.91B$591.84M-62.822,000Positive NewsBLCOBausch + Lomb2.0967 of 5 stars$15.32+2.0%$15.56+1.6%-16.3%$5.41B$4.89B-19.6013,500GKOSGlaukos4.6454 of 5 stars$92.40-1.6%$127.42+37.9%-33.7%$5.31B$383.48M-56.09780Positive NewsSLNOSoleno Therapeutics4.4506 of 5 stars$72.09+3.3%$115.09+59.7%-5.8%$3.84BN/A-17.4330Short Interest ↑NVSTEnvista3.6924 of 5 stars$21.25-0.3%$20.92-1.5%+11.5%$3.53B$2.51B66.3512,300Positive NewsAnalyst DowngradeLIVNLivaNova2.8818 of 5 stars$57.62-0.6%$59.71+3.6%+12.6%$3.15B$1.25B-14.822,900Positive NewsWRBYWarby Parker1.5287 of 5 stars$26.54+2.0%$24.06-9.3%+80.7%$2.80B$771.32M-379.593,780Positive NewsAnalyst UpgradeInsider Trade Related Companies and Tools Related Companies Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives iRhythm Technologies Alternatives Bausch + Lomb Alternatives Glaukos Alternatives Soleno Therapeutics Alternatives Envista Alternatives LivaNova Alternatives Warby Parker Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TMDX) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TMDX Stock Alerts